Press Releases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- FDB (First Databank, Inc.), the leading provider of clinical drug knowledge that helps improve medication-relate

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2018 and highlighted recent company achievements. Quarter-end cash and cash equivalents at September 30, 2018 were $219.8 million. “During the third quarter, we focused our activity on planning and initiating GlycoMimetics’ comprehensive clini

FREMONT, Calif.--(BUSINESS WIRE)-- KUKA, a global supplier of intelligent automation solutions, hosted the Fronius Technology Day event at its West Coast Fremo

IRVING, Texas--(BUSINESS WIRE)-- Fluor Corporation (NYSE: FLR) – Members of Fluor Corporation’s senior management team, including Chairman and

LEXINGTON, Ky.--(BUSINESS WIRE)-- A $1 million grant from the United Health Foundation will enable the University of Kentucky College of Dentistry (UKCD) to launch its “Eradicate Oral Cancer in Eastern Kentucky” project. The three-year project will raise public awareness of the symptoms of oral cancer and its links to heavy alcohol and tobacco use, provide approximately 1,000 oral cancer

IRVINE, Calif.--(BUSINESS WIRE)-- Boot Barn Holdings, Inc. (NYSE:BOOT), America’s largest western and work wear retailer, is partnering with Operation: Care and Comfort to support active military troops serving overseas with its semi-annual “Socks for Soldiers” event, which takes place during the months of May and November. Boot Barn is committed to serving the service men and wo

OXFORD, Conn.--(BUSINESS WIRE)-- RBC Bearings Incorporated (Nasdaq: ROLL), a leading international manufacturer of highly-engineered precision bearings and components for the industrial, defense and aerospace industries, today reported results for the second quarter of fiscal year 2019.  

NAARDEN, Netherlands, & MUNICH--(BUSINESS WIRE)-- Forbion, a leading European life science venture capital firm, today announces that it has led a €17m Series C financing of OMEICOS Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin, Germany. Forbion is the only new investor participating in the financing round, contributing €12.5m from its recently launched F

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dys

BERLIN & BOSTON--(BUSINESS WIRE)-- OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new investor Forbion. Existing investors Vesalius Biocapital II S.A. SICAR, Remig

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the third

MINNEAPOLIS--(BUSINESS WIRE)-- Apogee Enterprises, Inc. (Nasdaq: APOG) is scheduled to present at Baird’s 2018 Global Industrial Conference on Tuesday, November 6, 2018 in Chicago. Joseph F. Puishys, Apogee’s Chief Executive Officer, is scheduled to speak to investors at 2:30 p.m. Central Time on November 6. This presentation will be webcast. To access the we

ATLANTA--(BUSINESS WIRE)-- Floor & Decor Holdings, Inc. (NYSE: FND) today announced that the Company is scheduled to present at the Morgan Stanley Global Consumer & Retail Conference in New York City on Tuesday, November 13, 2018, at 1:40 pm Eastern Time. The audio portion of the presentation will be webcast live over the internet and can be accessed on the Company’s Investor Relations

MIAMI--(BUSINESS WIRE)-- Ryder System, Inc. (NYSE:R) Executive Vice President & Chief Financial Officer Art Garcia will present a company update at the Stephens Fall Investment Conference. Who:

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney